Immunic to attend June conferences
Analysis based on 10 articles · First reported Jun 10, 2026 · Last updated Jun 10, 2026
The announcement of Immunic's participation in multiple conferences could lead to increased investor interest and potential partnerships, positively impacting Immunic's stock price. Presentations on its drug pipeline, especially IMU-856, may generate positive sentiment within the biotechnology sector.
Immunic, a late-stage biotechnology company, announced its participation in several investor, industry, and scientific conferences throughout June 2026. Key executives, including CEO Ockelbo-Lundgren and President Jason Tay, will engage in fireside chats and one-on-one investor meetings at the H.C. Wainwright & Co. 7th Annual Neuro Perspectives Expert Summit. Immunic's management team will also attend the Cape Town International Convention Centre 2026 for partnering activities. Gbenga Genge, Global Head of Intellectual Property, will present work on IMU-856 at the EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 Symposium. Additionally, Immunic's medical team will participate in the 12th Congress of the American Academy of Neurology (EAN). These engagements aim to enhance Immunic's visibility, attract investors, and foster collaborations for its novel oral therapies for neurologic diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard